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Background: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces 
exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF dis-
continuation. Alternative dosing strategies may help patients continue their therapy.
Methods: In this multicenter, double-blind trial, 1,321 patients with severe COPD were random-
ized 1:1:1 to 4 weeks’ treatment with ROF 250 µg once daily (OD), 500 µg every other day 
(EOD), or 500 µg OD, each followed by ROF 500 µg OD for 8 weeks, plus standard therapy. The 
primary end point was the percentage of patients prematurely discontinuing study treatment.
Results: Patients in the 250 µg OD/500 µg OD group had significantly fewer treatment discon-
tinuations (odds ratio [OR] 0.66 [95% CI 0.47–0.93], p=0.017) and lower rates of AEs of interest 
such as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain (OR 0.63 
[95% CI 0.47–0.83], p=0.001) compared with those in the 500 µg OD group. Although rates 
of discontinuation and AEs of interest were numerically lower with ROF 500 µg EOD/500 µg 
OD, the difference was not significant (OR 0.76, p=0.114, and OR 0.78, p=0.091, respectively) 
compared with ROF 500 µg OD.
Conclusion: A dose of ROF 250 µg OD for 4 weeks before escalation to the approved 
maintenance dose of 500 µg OD resulted in reduced treatment discontinuation and improved 
tolerability.
Keywords: roflumilast, COPD, discontinuation, adverse event
Introduction
Severe exacerbations of COPD are associated with a poor prognosis.1–3 Roflumilast 
(ROF) is a selective, oral phosphodiesterase-4 (PDE4) inhibitor used for the treatment of 
patients with severe COPD associated with chronic bronchitis and a history of exacer-
bations.4 Previous studies have shown that ROF as an add-on to inhaled COPD therapy 
reduces exacerbations in this patient population.5,6 More recently, this has been shown 
in the ROF and Exacerbations in patients receiving Appropriate Combination Therapy 
(REACT) study – in patients using ROF therapy in addition to an inhaled corticosteroid 
(ICS)/long-acting beta agonist (LABA) ± long-acting muscarinic antagonist (LAMA) 
combination7 – a finding most evident in those with a history of hospitalization.8
Patients initiating treatment with the approved 500 µg dose of ROF may report side 
effects in the first few weeks, including diarrhea, nausea, headache, insomnia, abdomi-
nal pain, loss of appetite and a reduction in body weight.4,6,9 These are predominantly 
mild to moderate in severity and, with the exception of body weight reduction, typically 
transient – often resolving within the first few weeks of treatment.10 However, they 
are a common cause of early treatment discontinuation. Overall rates of discontinu-
ations for patients taking 500 µg of ROF in recent 52-week clinical trials have been 
in the region of 30%,7,11 although the rates of discontinuation are thought to be higher 
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in clinical practice.12 Therefore, alternative dosing strategies 
to improve tolerability over the first few weeks of treatment 
may help patients continue their therapy.
The present study, referred to as OPTIMIZE (Clinical-
Trials.gov: NCT02165826), investigated whether treatment 
discontinuation rates could be reduced and tolerability could 
be improved by using a reduced dose of ROF for a short initial 
treatment period. Phase I dose-ranging and modeling stud-
ies13 have previously suggested that a daily dose of 250 µg is 
associated with an improved side effect profile compared with 
the approved 500 µg dose. However, the 250 µg dose is less 
efficacious, associated with less forced expiratory volume in 
1 second (FEV
1
) improvement, than the 500 µg dose14,15 and 
is not appropriate for long-term maintenance therapy.
The 12-week OPTIMIZE study evaluated the tolerabil-
ity and discontinuation rate associated with a daily dose of 
250 µg ROF for the first 4 weeks, before escalation to 500 µg 
for 8 weeks. In a parallel treatment arm, 500 µg was given 
on alternate days for the first 4 weeks of treatment, before 
increasing to 500 µg daily. The results of both up-titration 
strategies were compared with 500 µg dose daily, taken 
continuously for 12 weeks. Pharmacokinetic analyses were 
undertaken to evaluate drug exposure in patients receiving the 
three treatment strategies to assess any correlation between 
drug exposure and ability to tolerate ROF.
Methods
Patients
Patients aged $40 years with a history of COPD associated 
with chronic productive cough, $1 moderate or severe exac-
erbation in the previous 12 months, and who were former/
current smokers (history of $10 pack-years) were eligible for 
enrollment. A post-bronchodilator FEV
1
 #50% of predicted 
and an FEV
1
/forced vital capacity (FVC) ratio ,70% were 
required. Patients had to be receiving standard of care COPD 
treatment (LABA or LAMA or a combination of the two 
for at least 12 weeks). Patients were excluded if they had a 
COPD exacerbation ongoing at screening, a lower respiratory 
tract infection unresolved within 4 weeks prior to screening, 
asthma/other relevant lung disease, or known α1-antitrypsin 
deficiency (refer Supplementary materials for the full list 
of inclusion/exclusion criteria). ICS and theophylline were 
permitted if taken at a constant daily dose for 12 weeks prior. 
All patients involved in the OPTMIZE trial provided their 
written informed consent.
study design and interventions
OPTIMIZE was a multicenter, double-blind, Phase III ran-
domized trial conducted over 12 weeks, which included an 
initial 4-week up-titration period. All patients discontinuing 
the trial were offered the opportunity to enter an 8-week 
open-label down-titration phase, during which they received 
ROF 250 µg OD (Figure S1).
Patients were randomized (by a computerized interactive 
voice response system/interactive web response system) to 
one of three treatment regimens (1:1:1) (Figure S1): ROF 
250 µg once daily (OD) for 4 weeks and then 500 µg OD 
thereafter (250 µg OD/500 µg OD), ROF 500 µg every 
other day (EOD) for 4 weeks and then 500 µg OD thereafter 
(500 µg EOD/500 µg OD) or ROF 500 µg OD for 12 weeks 
(500 µg OD). Patients continued receiving their usual main-
tenance therapy.
The first 4 weeks (up-titration) of the trial were double 
blinded, and the remaining 8 weeks (maintenance period) 
were single blinded, with only the sponsor and investigators 
aware that the patient was receiving ROF 500 µg OD. The 
original randomized treatment regimen remained blinded to 
all parties involved in the study for the duration of the study. 
ROF 250 and 500 µg and placebo were supplied as identical 
white, round, biplane tablets in wallet cards containing 
20 tablets, with identical labeling and packaging.
Patients attended clinics at screening, randomization and 
Weeks 2, 4, 8 and 12. Those discontinuing and entering the 
down-titration phase also attended clinic on Weeks 2, 4 and 8 
of the down-titration. Study medication was accounted for 
at each visit to assess compliance.
The study protocol was approved by each respective 
institutional review board and followed established good 
clinical practice guidelines. A list of all approving institu-
tional review boards is available in Table S1. All patients 
gave written informed consent for this study.
Outcomes and end points
The primary end point was the percentage of patients prema-
turely discontinuing study treatment for any reason during 
the 12-week study period. Secondary end points included the 
percentage of patients with adverse events (AEs) of interest 
(diarrhea, nausea, headache, decreased appetite, insomnia and 
abdominal pain) during the trial, percentage of patients pre-
maturely discontinuing study treatment for any reason during 
the down-titration phase, and change in pre-bronchodilator 
FEV
1
 during both the trial and the down-titration phase. 
The six types of AEs of interest used to evaluate tolerability 
were selected as they are the most common AEs associated 
with ROF treatment, the main reason for treatment discon-
tinuation, and assumed to be related to PDE4 inhibition.
Safety assessments included monitoring AEs and assess-
ment of Columbia-Suicide Severity Rating Scale (C-SSRS), 
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body weight, and body mass index (BMI). AEs of interest 
(occurrence and intensity) were assessed on a daily basis 
using diary cards. Intensity (mild/moderate/severe) was 
evaluated using a 7-point Likert scale.
Pharmacokinetic evaluations
Pharmacokinetics (PK) of ROF and ROF N-oxide were 
measured using 6 mL blood samples by Pharmaceutical 
Product Development (Middleton, WI, USA) using a 
high-performance liquid chromatography tandem mass 
spectrometer, as described previously.16
An integrated population PK (popPK) model was devel-
oped to predict individual ROF/ROF N-oxide exposure 
levels and total PDE4 inhibitory activity (tPDE4i) levels 
and assess whether patients unable to tolerate ROF 500 µg 
OD have drug exposure with 250 µg OD, similar to patients 
on a 500 µg OD dose. The integrated popPK model was 
developed from an earlier base model in which the structural 
parameters were fixed to estimates from a dataset of 21 
Phase I and two Phase II/III studies.16 This base model used 
combined REACT/OPTIMIZE datasets.7,17
statistical analyses
A hierarchical testing approach was followed; if significance 
(5%) was not reached, subsequent tests were exploratory. 
The hierarchy of testing for the null hypothesis was first: if 
the percentage of patient discontinuations on ROF 250 µg 
OD/500 µg were not lower than or equal to that on ROF 
500 µg OD by Week 12, then the percentage of patient 
discontinuations on ROF 500 µg EOD/500 µg OD were not 
lower than or equal to that on ROF 500 µg OD by Week 12 
(refer Supplementary materials for full list).
The primary end point and secondary safety end points 
were based on the safety analysis set (SAS) and performed 
using a logistic regression model. For the primary end point 
and AEs of interest, the treatment odds ratio (OR) and relative 
risk (RR) between groups18 were calculated. The secondary 
efficacy end point, change in pre-bronchodilator FEV
1
, was 
based on the full analysis set (FAS) and analyzed using an 
analysis of covariance model.
Additional post hoc exploratory analyses were undertaken 
to further assess whether weight loss on ROF was related to, 
1) baseline BMI, and 2) gastrointestinal AEs and/or decreased 
appetite (no formal statistical testing performed).
For calculation of sample size, rates of discontinuation 
for any reason were estimated based on pooled data from the 
ROF COPD pivotal studies,6,9 which included a similar patient 
population to the OPTIMIZE study. Assuming a discontinu-
ation rate of 20% with ROF 500 µg OD and 13% with either 
up-titration regimen, a total of 441 patients per treatment arm, 
1,323 overall, would provide 80% power to declare superior-
ity of each of ROF 250 µg OD/500 µg OD and ROF 500 µg 
EOD/500 µg OD versus ROF 500 µg OD for 12 weeks.
Results
Patients
The study was conducted at 161 sites across 15 countries 
(refer Supplementary materials for full list) between April 
2014 and October 2015. In total, 1,323 patients were ran-
domized, of whom 1,321 received treatment. A total of 
104 patients entered the down-titration phase (Figure 1). 
Data presented hereafter are for the 12-week trial popula-
tion; data on the down-titration phase are included in the 
Supplementary materials.
Baseline characteristics were generally balanced across 
the treatment arms (Table 1). Patients had a mean age of 
64.6 years and were predominantly male (74.4%). Compli-
ance with study medication ranged from 101% to 104% 
across treatment arms. Demographic and baseline charac-
teristics of patients who entered the down-titration phase are 
presented in Table S2.
study discontinuations
The greatest between-group difference in discontinuations 
occurred in the first few weeks of treatment (Figure 2A). 
Significantly fewer patients discontinued treatment (for any 
reason) in the ROF 250 µg OD/500 µg OD group compared 
with the ROF 500 µg OD group (18.4% versus 24.6%; RR 0.72 
[95% CI 0.54–0.95], OR 0.66 [95% CI 0.47–0.93], p=0.017; 
Figure 2B). There were fewer treatment discontinuations in 
the ROF 500 µg EOD/500 µg OD group compared with the 
ROF 500 µg OD group, but this difference did not reach sta-
tistical significance (20.1% versus 24.6%; RR 0.81 [95% CI 
0.62–1.05], OR 0.76 [95% CI 0.55–1.07], p=0.114; Figure 2). 
Based on the hierarchical testing approach, all interpretations 
of p-values after the second hierarchical test are exploratory.
Tolerability
Significantly fewer patients experienced AEs of interest in 
the ROF 250 µg OD/500 µg OD arm compared with the 
ROF 500 µg OD arm (45.4% versus 54.2%; RR 0.79 [95% 
CI 0.66–0.91], OR 0.63 [95% CI 0.47–0.83], p=0.001; 
Figure 3). The frequency of all AEs of interest was lower, 
and the median time to onset was longer in the ROF 250 µg 
OD/500 µg OD arm compared with the ROF 500 µg OD 
arm (Table S3). The proportion of patients reporting AEs 
of interest was numerically lower in the ROF 500 µg 
EOD/500 µg OD arm compared with the 500 µg OD arm, but 
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Table 1 Baseline patient characteristics
Characteristics ROF 250 OD/ROF 
500 OD (n=441)
ROF 500 EOD/ROF 
500 OD (n=437)
ROF 500 
OD (n=443)
age, years 64.2 (7.8) 65.0 (8.2) 64.6 (8.4)
Male, n (%) 320 (72.6) 325 (74.4) 338 (76.3)
White, n (%) 405 (91.8) 399 (91.3) 405 (91.4)
BMI, kg/m2 26.4 (6.0) 26.01 (5.6) 26.46 (5.9)
Cigarette pack years 38.1 (17.5) 40.2 (19.2) 37.6 (17.7)
Current smoker, n (%) 213 (48.3) 198 (45.3) 196 (44.2)
Pre-bronchodilator FEV1, l 1.0 (0.3) 1.0 (0.3) 1.0 (0.3)
Pre-bronchodilator FVC, L 2.3 (0.7) 2.3 (0.7) 2.3 (0.7)
% predicted FeV1 36.0 (8.8) 36.7 (8.8) 36.0 (9.5)
Post-bronchodilator FEV1/FVC 0.46 (0.1) 0.47 (0.1) 0.46 (0.1)
% FeV1 reversibility 7.1 (12.0) 6.45 (14.4) 7.4 (11.4)
#2 exacerbations, n (%) 435 (98.6) 427 (97.7) 432 (97.5)
.2 exacerbations, n (%) 6 (1.4) 9 (2.1) 9 (2.0)
Most commonly reported 
concomitant medication, n (%)a
440 (99.8) 437 (100.0) 443 (100.0)
laMa (tiotropium bromide) 245 (55.6) 235 (53.8) 225 (50.8)
ICs/laBa (seretide, budesonide) 202 (45.8) 197 (45.0) 217 (48.9)
Theophylline 80 (18.1) 85 (19.5) 80 (18.1)
Notes: Data are taken from the SAS and expressed as mean (SD) unless otherwise stated. aTaken in $10% of all patients.
Abbreviations: BMI, body mass index; EOD, every other day; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid; 
LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; ROF, roflumilast; SAS, safety analysis set; SD, standard deviation; 250, 250 µg; 
500, 500 µg.
Figure 1 Patient disposition.
Notes: aA pre-treatment event is defined as any untoward medical occurrence in a patient who had signed written informed consent to participate in a study, but prior to 
administration of any study medication; it did not necessarily have to have a causal relationship with study participation.
Abbreviations: EOD, every other day; LTFU, lost to follow-up; OD, once daily; ROF, roflumilast; 250, 250 µg; 500, 500 µg.
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the difference was not significant (48.3% versus 54.2%; OR 
0.78 [95% CI 0.59–1.04, p=0.091]); (Figure 3 and Table S3). 
The AEs of interest were predominantly mild or moderate 
(Table S4) and of short duration (2–4 days; data include dis-
continued patients; Table S3). For each treatment arm, among 
patients who discontinued, the most commonly reported AE 
of interest was diarrhea (19.8%, 31.8%, and 33%, in the ROF 
250 µg OD/500 µg OD, 500 µg EOD/500 µg OD and the 
500 µg OD arms respectively; Table S5).
The percentage of patients who withdrew from treatment 
due to AEs was 13.2%, 15.3%, and 17.4% with ROF 250 µg 
OD/500 µg OD, 500 µg EOD/500 µg OD, and 500 µg OD, 
respectively. AEs that most commonly led to discontinuation 
in the ROF 250 µg OD/500 µg OD arm, 500 µg EOD/500 µg 
OD arm, and 500 µg OD arm, were diarrhea (3.6%, 6.4%, 
and 8.1% of patients, respectively), decreased appetite 
(3.6%, 4.6%, and 7.4% of patients, respectively), and nausea 
(3.9%, 3.7%, 6.1% of patients, respectively).
Overall, 63.7% of patients experienced any AE: 61.2%, 
64.3%, and 65.7% with ROF 250 µg OD/500 µg OD, 
500 µg EOD/500 µg OD, and 500 µg OD, respectively. The 
most frequently reported AEs were those assessed as AEs 
Figure 2 (A) Probability of patients continuing the 12-week trial for any reason (SAS). (B) Percentage of patients discontinuing for any reason.
Abbreviations: CI, confidence interval; EOD, every other day; OD, once daily; OR, odds ratio; ROF, roflumilast; SAS, safety analysis set; 250, 250 µg; 500, 500 µg.
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of interest. During the trial, 4.6% of patients experienced 
a serious AE and six deaths were reported (three in the 
250 µg OD/500 µg OD arm [COPD, cardiac failure, and 
cardiopulmonary failure], one in the 500 µg EOD/500 µg 
OD arm [pneumothorax spontaneous], and two in the 500 µg 
OD arm [lung adenocarcinoma and myocardial infarction]). 
Suicidal ideation was reported in one patient in the ROF 
500 µg OD group during the trial, and this patient discon-
tinued treatment as a result.
Weight decrease was self-reported by 2.3%, 2.1%, and 
3.8% of patients who received 250 µg OD/500 µg OD, 
500 µg EOD/500 µg OD, and 500 µg OD, respectively. 
Reduction in body weight was evident from Week 2 and 
was of a similar magnitude across treatment groups (mean 
decrease 1.02, 0.82, and 0.98 kg, respectively; Figure 4). 
In post hoc analyses, weight loss tended to be greater in 
patients with a BMI .25 kg/m2 compared with those with a 
BMI #25 kg/m2 in all treatment groups (Table S6).
Figure 3 summary of aes of interest.
Note: Percentage of patients with $1 ae to evaluate tolerability.
Abbreviations: AE, adverse event; CI, confidence interval; EOD, every other day; OD, once daily; OR, odds ratio; ROF, roflumilast; 250, 250 µg; 500, 500 µg.
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Figure 4 Mean change in body weight.
Notes: Measurements are mean, with bars showing SD. Vend was the last measurement obtained before dropout/study completion.
Abbreviations: EOD, every other day; OD, once daily; ROF, roflumilast; SD, standard deviation; 250, 250 µg; 500, 500 µg.
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lung function
Improvements from baseline in pre-bronchodilator FEV
1
 
over the trial were minimally different between ROF 250 µg 
OD/500 µg OD, 500 µg EOD/500 µg OD, and 500 µg OD 
treatment groups (least squares [LS] mean change 90, 130, 
and 110 mL, respectively).
Pharmacokinetics
Individual PK parameters and tPDE4i values were derived 
for 1,238 patients with at least one quantifiable PK sample,17 
including 101 patients who discontinued the 12-week trial and 
entered the down-titration phase, of whom 76 entered after 
not tolerating at least one dose of ROF 500 µg. Patients who 
discontinued ROF 500 µg OD in the trial because of AEs of 
interest had a slightly higher median tPDE4i (.10%) than 
those able to tolerate this dose (median tPDE4i level: 1.28 and 
1.16, respectively; Figure 5). However, as expected with 
linear PK, reducing the dose to 250 µg OD in these patients 
reduced tPDE4i to below that typically observed in patients 
able to tolerate the 500 µg OD (median tPDE4i level: 0.65).
Figure 5 Comparison of tPDE4i levels achieved with ROF 500 µg or 250 µg according to whether patients were able to tolerate the dose.
Notes: Medians in trial and down-titration phase. aFor consistency with previous popPK models, the list of preferred terms included in the AEs of interest for the popPK 
model is larger than that used to investigate safety in this study (Table s7). error bars are 95% CI.
Abbreviations: AE, adverse event; CI, confidence interval; OD, once daily; popPK, population pharmacokinetics; ROF, roflumilast; tPDE4i, total phosphodiesterase-4 
inhibitory activity; 250, 250 µg; 500, 500 µg.
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Discussion
Although the side effects that may occur soon after initia-
tion of ROF are often transient in nature and predominantly 
mild to moderate in severity, they are a common reason 
for discontinuing treatment. Using an alternative reduced 
dosing regimen for a short initial treatment period (as used 
successfully with other systemic therapies)19–22 is one strategy 
to help increase the acceptability of ROF treatment and help 
patients stay on therapy. The OPTIMIZE study supports this 
concept. While use of a reduced dose of ROF as long-term 
maintenance therapy may not induce sufficient PDE4 inhi-
bition to exert the clinical efficacy of the 500 µg dose,14,15 
it can be used as part of an up-titration regimen to overcome 
tolerability issues in the first weeks of treatment and hence 
reduce discontinuation rates.
Initiating ROF at a 250 µg daily dose for 4 weeks, before 
escalating to 500 µg daily dose for 8 weeks, was associated 
with a statistically significant decrease in the percentage of 
patients discontinuing treatment for any reason and reporting 
side effects of interest. The overall discontinuation rate for 
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patients taking ROF 500 µg daily in the current study was in 
line with that observed in recent ROF clinical trials,7,11 and 
for patients starting at the reduced dosing of 250 µg daily, the 
odds of early discontinuation and experiencing side effects 
of interest were 34% and 37% lower (RR reduction 28% and 
21%). Patients starting ROF at 500 µg on alternate days also 
reported fewer side effects and lower treatment discontinua-
tion rates, but this was not significantly different compared 
with the 500 µg daily regimen.
The AEs of interest selected as a focus for OPTIMIZE 
study have previously been identified as limiting tolerability 
to ROF.4,6,9 Diarrhea and other gastrointestinal side effects 
particularly, have been perceived as a barrier to ROF treat-
ment. Diarrhea accounted for approximately one-third of 
discontinuations with the 500 µg dose, and this was lowered 
to approximately 20% with reduced dosing.
The mechanisms by which ROF causes nausea and 
diarrhea are believed to be distinct. Nausea is mediated by 
PDE4-D; located outside the blood–brain barrier, this subtype 
is accessible to ROF.23 The mechanism behind diarrhea is 
less clear; activators of the cystic fibrosis transmembrane 
conductance regulator (CFTR) are known to be potent induc-
ers of diarrhea, and it is thought that PDE4 inhibition could 
activate this mechanism.24,25
Weight loss is a known systemic side effect of ROF6,9 and 
has been reported with both selective and nonselective PDE 
inhibitors.26 However, it did not appear to be a significant rea-
son for discontinuation in OPTIMIZE, accounting for ,1% 
of discontinuations overall. Reductions in body weight were 
similar between all three dosing regimens and comparable 
with previous studies when treatment length is taken into 
account.6,9 Absolute weight loss tended to be more pronounced 
in patients with a higher baseline BMI and in those who also 
experienced gastrointestinal side effects or loss of appetite 
with ROF (as seen previously).6 While the mechanism by 
which ROF causes weight decrease remains to be fully elu-
cidated, it is thought to be related to the effects of increased 
cAMP on signaling pathways regulating lipolysis.15
Frequency of individual side effects of interest was 
always lowest in the 250 µg/500 µg OD group followed by 
the 500 µg EOD/500 µg OD group and then the 500 µg OD 
group. One exception was abdominal pain; the reason for this 
was unclear. Frequencies of some side effects of interest were 
higher in this study than those reported in previous studies;7,11 
one explanation for this finding may be that OPTIMIZE, in 
contrast to previous studies, used a daily patient-assessed 
diary method to record side effects of interest. As OPTIMIZE 
did not include a placebo arm, the impact of the use of daily 
diary cards on side effect rates cannot be assessed. Addition-
ally, levels of theophylline were not known in the 80 patients 
who were taking it, but may have contributed to increased 
reporting of side effects in these patients.
The 250 µg daily dose was selected as the appropriate 
reduced dose following modeling studies, suggesting an 
improved side effect profile, compared with the 500 µg main-
tenance dose.13 Lung function measurements in OPTIMIZE 
revealed that the initial 4-week up-titration regimens did 
not appear to reduce the effect of the drug on lung function. 
FEV
1
 improvements of ~100 mL in all treatment arms were 
observed; this improvement is at the upper range of changes 
compared with previous studies.6,7,9,11
Following oral dosing, ROF is rapidly converted by cyto-
chrome P450 enzymes to its active metabolite ROF N-oxide, 
which contributes to ~90% of the tPDE4i activity.27,28 ROF 
N-oxide is primarily cleared by the enzyme CYP3A4, and a 
number of covariates can affect the activity.29,30 PK analyses 
found that patients who discontinued ROF 500 µg daily in 
the main 12-week trial of OPTIMIZE because of side effects 
of interest had a slightly higher median tPDE4i than those 
able to tolerate this dose. It is plausible that higher tPDE4i 
levels lead to more potential off-target effects of ROF such 
as nausea and diarrhea. However, as expected with linear PK, 
reducing the dose to 250 µg daily in these patients reduced 
tPDE4i to well below that typically observed in patients able 
to tolerate 500 µg daily. However, a daily dose of 250 µg 
should not be considered suitable as a therapeutic mainte-
nance dose, as efficacy in exacerbation reduction has not 
been adequately demonstrated in clinical studies.
A recent Korean study retrospectively analyzed data 
from 85 patients with severe/very severe COPD taking either 
500 µg or 250 µg ROF daily, up-titrated to 500 µg daily up 
to 3 months after. There was a trend toward fewer AEs and 
discontinuations with the reduced initial dose.31 Similarly, 
a recent PK modeling analysis13 predicted that ROF 250 µg 
daily and 500 µg on alternate days were associated with 
lower plasma drug concentrations, lower tPDE4i, and lower 
incidence of diarrhea, nausea, and headache compared with 
ROF 500 µg daily. These data support the findings of the 
OPTIMIZE study.
Limitations of the current study include the lack of a 
placebo arm, the low sample size in the down-titration phase, 
and a short study duration of 12 weeks compared with a 
long-term maintenance treatment. Nonetheless, the study 
population is one of the largest to investigate side effects in 
a targeted COPD population, and gives us confidence in the 
validity of our conclusions.
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Conclusion
Starting ROF treatment at 250 µg daily for 4 weeks before 
increasing to the therapeutic maintenance dose of 500 µg 
daily reduced treatment discontinuations and improved 
the tolerability profile compared with initiating treatment 
at 500 µg daily. In practice, this should help patients with 
COPD to stay longer on treatment with the therapeutic dose. 
However, use of 250 µg OD as long-term maintenance 
therapy may not induce sufficient PDE4 inhibition to exert 
clinical efficacy.
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